April 23, 2017

Agios Pharmaceuticals Inc (AGIO) Director Sells $112468.64 in Stock

21 April 2017, 02:17 | Megan Pierce

Essentially, a price target is an individual analyst's expectation on the future price of a security, usually a stock.

On 4/3/2017 Scott Biller, Insider, sold 2,146 with an average share price of $58.03 per share and the total transaction amounting to $124,532.38.

Agios Pharmaceuticals, a biopharmaceutical company, which engages in applying scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism. They now have a Dollars 45 price target on the stock.

On Thursday, March 23rd, Lewis Clayton Jr. BNP Paribas Arbitrage SA now owns 14,388 shares of the biopharmaceutical company's stock valued at $760,000 after buying an additional 2,440 shares during the period. Highest potential price target is expected at $90.00 however minimum price target advised by analysts is $48.00.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) CEO David P. Schenkein sold 3,000 shares of the business's stock in a transaction dated Monday, April 3rd. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price.

The stock's 50 day moving average is 53.56 and its 200 day moving average is 50.55.

What Trump's H-1B Order Means For Indian IT Companies: 10 Points
In an announcement, the White House said H-1B visas should bring the highly talented and paid work to the United States. USA authorities will also conduct site visits to check on employers who hire H-1B visa holders over Americans.

Pakistan court to decide on accusations against PM's family
The news comes as a drawn-out investigation related to the "Panama Papers" leaks, which revealed the Sharif family's offshore wealth, has neared conclusion.

Court Rulings Block 2 Scheduled Executions Today In Arkansas
As such, she granted the TRO - at the hearing on Wednesday and in a written order issued a little before noon Thursday. Preparations will continue "pending the outcome of appeals at both the state and federal levels", Graves said.

Analysts gives Agios Pharmaceuticals Inc (NASDAQ:AGIO) a mean recommendation of 1.90. Beta value of the stock stands at 2.00. Agios Pharmaceuticals's revenue for the quarter was up 264.5% compared to the same quarter previous year. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.51) by $0.17. The firm earned $22.65 million during the quarter, compared to the consensus estimate of $10.89 million. Rhumbline Advisers boosted its stake in Agios Pharmaceuticals by 3.4% in the third quarter. The company's quarterly revenue was up 264.5% compared to the same quarter a year ago. Annual EPS Growth of past 5 years is 10.60%. (AGIO) has a trading volume of 4.11 Million shares, with an average trading volume of 453120 shares - with shares dropping to a 52 week low of $35.84, and the company's shares hitting a 52 week high of $ 67.74. The legal version of this story can be read at If you are reading this report on another site, it was illegally stolen and republished in violation of United States & worldwide copyright and trademark legislation. Zacks Investment Research cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Tuesday. The firm has "Neutral" rating given on Friday, August 19 by BTIG Research. Beech Hill Advisors Inc. purchased a new stake in Agios Pharmaceuticals during the third quarter valued at approximately $217,000.

At the time of writing, Agios Pharmaceuticals, Inc. Janney Montgomery Scott upgraded shares of Agios Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $57.00 price objective for the company in a research report on Thursday, February 16th. The Stock opened today's session at $27 and now the price is hovering at $26.87 by showing decrease of -0.07 percent. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. They now have a Dollars 46 price target on the stock.

Large investors have recently modified their holdings of the company.

05/08/2015 - MLV & Co began new coverage on Agios Pharmaceuticals, Inc. giving the company a "buy" rating. The volatility in the previous week has experienced by 4.84% and observed of 4.60% in the previous month.97.60% ownership is held by institutional investors while insiders hold ownership of 0.50%. Capital International Ltd. CA raised its stake in shares of Agios Pharmaceuticals by 31.0% in the fourth quarter.

06/13/2016 - Agios Pharmaceuticals, Inc. was upgraded to "overweight" by analysts at JP Morgan.

Other News

Trending Now

2 officers shot responding to robbery in Seattle
Police are searching for a possible third suspect: A black man with a dark complexion, 5 feet 11 inches tall and 250 pounds. "Wow. A female suspect struck one of the officers with a bottle and a third suspect opened fire, wounding the officers, police said.

DXC Technology Company (NYSE:DXC) & Medical Properties Trust, Inc
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . On average, equities research analysts predict that Medical Properties Trust, Inc. will post $0.98 EPS for the current year.

South Korea-US trade deal will be reviewed, reformed - VP Pence
In Wisconsin on Tuesday, Trump said that how much North Korea's leader desires peace will be a deciding factor in easing tensions. Pence said after the meeting that Trump believes it is in America's interest to negotiate economic deals on a bilateral basis.

Champions League: Juventus deny Barcelona another Camp Nou miracle
They had 19 shots on the night - yet only one on target as Juve avenged their defeat against the same opponents in the 2015 final. Messi tumbled face first into the turf, and showed a small scratch that bled on his cheek once he got back on his feet.

Drive-thru pot stores are now a reality
When the "for sale" sign went up on the Valley Car Wash in Parachute , Colo., Mark Smith didn't waste a second. So he bought the auto wash and set to work transforming the vehicle bay into a new place to sell his wares.

What Do Analysts Say About GNC Holdings Inc. (GNC)
In addition to Vetr Inc. reporting its stock price target , a total of 13 brokerages have issued a ratings update on the company. In terms of Buy/Sell recommendations, analysts have a consensus rating of 3.18 on the shares of GNC Holdings Inc (NYSE: GNC ).

Texas Reps. initially pass bill to regulate rideshare companies statewide
The House Committee on State Affairs is scheduled to hear public testimony as soon as the low-chamber adjourns for the day. A bill that sets new limits on the state's top 10 percent university admissions law is advancing in the state Senate .

Manchester City climb to third with Southampton victory
He's a real defender, hopefully he can be fit until the end of the season because he's an important player for us". Everton are lining up a summer move for Manchester City captain Vincent Kompany, according to the Daily Mirror .

Does $0.41 justifies Palatin Technologies Inc. (PTN) shares?
Advisors LP bought a new position in shares of Palatin Technologies during the third quarter worth about $1,289,000. The corporation holds 138.06 million outstanding shares and its 135.55 million shares were floated in the market.

Tillerson says USA reviewing possibility of relisting NK as terror sponsor
Mr Mattis credited China with trying to help get the North Korea situation "under control" with the goal of denuclearising the peninsula.